Medically significant infections are increased in patients with juvenile idiopathic arthritis treated with etanercept: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study

Arthritis and Rheumatology

Volumn 67, Issue 9, 2015, Pages 2487-2494

  Davies, Rebecca ^a   Southwood, Taunton R ^b   Kearsley Fleet, Lianne ^a   Lunt, Mark ^a   Hyrich, Kimme L ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE; ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ARTHRITIS, JUVENILE; BACTERIAL INFECTIONS; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; VIRUS DISEASES;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; ARTHRITIS, JUVENILE; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR; VIRUS DISEASES;

EID: 84940118360     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39197     Document Type: Article

References (25)

1. Ravelli A, Martini A., Juvenile idiopathic arthritis. Lancet 2007; 369: 767-78.
2. Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, et al., Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J Rheumatol 2012; 39: 1287-90.
3. Morishita K, Petty R, Cairns R, Bolaria R, Cabral D, Turvey S., Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-α therapy: a case series. Clin Rheumatol 2010; 29: 677-81.
4. Le Saux N, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Biologic response modifiers to decrease inflammation: Focus on infection risks. Paediatr Child Health 2012; 17: 147-54.
5. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al, on behalf of the British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50: 124-31.
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V., Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
7. Hurd A, Beukelman T., Infectious complications in juvenile idiopathic arthritis. Curr Rheumatol Rep 2013; 15: 327.
8. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al, on behalf of the SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012; 64: 2773-80.
9. Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al., Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 2012; 51: 1407-15.
10. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al., Long-term followup on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009; 68: 635-41.
11. Renaud C, Ovetchkine P, Bortolozzi P, Saint-Cyr C, Tapiero B., Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker. Eur J Pediatr 2011; 170: 657-60.
12. Holl-Wieden A, Beer M, Marx A, Bonfig R, Tappe D, Girschick HJ., Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int 2008; 28: 819-22.
13. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al., Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68: 519-25.
14. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al., International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
15. National Institute for Health and Care Excellence (NICE). Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. March 2002. URL: https://www.nice.org.uk/guidance/ta35/chapter/1-guidance.
16. Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, et al., Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 2011; 50: 189-95.
17. Brown EG, Wood L, Wood S., The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109-17.
18. Singh G, Athreya BH, Fries JF, Goldsmith DP., Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 1761-9.
19. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al, for the Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-66.
20. Royston P., Multiple imputation of missing values: update. Stata J 2005; 5: 188-201.
21. Southwood TR., Paediatric rheumatic disease: treatment of JIA in the biologic era: what are we waiting for? Nat Rev Rheumatol 2014; 10: 132-4.
22. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE., Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300.
23. Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, et al., Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65: 353-61.
24. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al., Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-93.
25. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al., Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20.